NEW YORK /PRNewswire/ — Columbia Care LLC (“CC”), a leading national medical marijuana product development, manufacturing and distribution company, has announced the launch of its line of controlled-dose, solid-fill medical cannabinoid capsules. These capsules are the first and only pharmaceutical quality, controlled-dose, solid-fill pills available to patients, not only in the United States, but in any jurisdiction where marijuana is available for medical use. Formulated using the full range of active ingredients from plants grown in CC’s natural, organic agricultural process, these proprietary capsule lines will offer a variety of concentrations in a more accessible, subtle and convenient delivery form to patients, in particular, those with fine motor control limitations caused by neuropathy or those who live with chronic illnesses such as multiple sclerosis, epilepsy and inflammatory bowel disease.
“Columbia Care’s mission is to improve lives. To accomplish this, we are committed to pushing the boundaries of innovation to provide patients with safe and consistent medicines that enhance access, efficacy and privacy. The launch in New York of our controlled-dose, solid-fill capsule line is a tangible manifestation of these efforts,” said Columbia Care CEO Nicholas Vita. “We are proud to offer this new, proprietary, pharmaceutical formulation as the first-of-its-kind in the United States to enhance patient access while re-setting the standard and expectations for care, safety and quality for the entire industry.”
Columbia Care’s patent-pending controlled-dose, solid-fill capsules contain a powder, that unlike liquid-fill capsules, do not carry the risk of leakage. This new product will make administering and storing medical marijuana medicines more convenient, consistent and efficacious due to the precision of dosing. In some cases, this delivery method may extend the intended benefits of the medicine beyond that of a tincture or vaporization oil, resulting in fewer doses per day and potentially better long-term symptom control.
The New York State Department of Health approved Columbia Care’s controlled-dose, solid-fill capsule for dispensing in all four of Columbia Care’s New York-based dispensaries. The new capsule will be offered in three different formulations to serve the needs of individual patients and their particular conditions. In 2017, Columbia Care plans to make these products available in several of its other licensed jurisdictions thoroughout the United States beginning with Arizona, Delaware, Illinois, Massachusetts, and Washington D.C.
Filed Under: Drug Discovery